Antipsychotic and other medications used in the treatment of schizophrenia place a burden on the cholinergic subsystems of the brain, which have been associated with increased cognitive impairment in the disorder. This study sought to examine the neurobiologic correlates of the association between serum anticholinergic activity (SAA) and cognitive impairments in early schizophrenia. Neurocognitive performance on measures of memory and executive function, structural magnetic resonance imaging (MRI) scans, and SAA assays were collected from 47 early course, stabilized outpatients with schizophrenia or schizoaffective disorder. Voxel-based morphometry analyses employing general linear models, adjusting for demographic and illness-related confounds, were used to investigate the associations between SAA, gray matter morphology, and neurocognitive impairment. SAA was related to working memory and executive function impairments. Higher SAA was significantly associated with lower gray matter density in broad regions of the frontal and medial-temporal lobes, including the dorsolateral prefrontal cortex (DLPFC), hippocampus, and striatum. Lower gray matter volume in the left DLPFC was found to significantly mediate the association between SAA and working memory impairment. Disease-and/or medication-related cholinergic dysfunction may be associated with brain volume abnormalities in early course schizophrenia, which may account for the association between SAA and cognitive dysfunction in the disorder.
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Introduction
Schizophrenia involves broad impairments in neurocognitive functioning (Saykin et al., 1994; Heinrichs and Zakzanis, 1998) , and these deficits have been associated with poor functional outcome (Green et al., 2000) . Evidence is emerging that at least some of the neurocognitive impairments individuals with schizophrenia experience are associated with increased anticholinergic activity, perhaps due to the antimuscarinic properties of different pharmacotherapies (Bymaster et al., 2003; Chew et al., 2008) or dysfunction in the cholinergic system associated with the disorder itself (Raedler et al., 2007) . Antipsychotic and other supplemental pharmacological treatments for schizophrenia often produce anticholinergic-associated effects beyond their primary pharmacological targets (Raedler et al., 2000; Raedler et al., 2003a) , which have been repeatedly shown to be associated with exacerbation of neurocognitive impairment, particularly in memory (e.g., Tracy et al., 2001; Minzenberg et al., 2004) . In addition, recent evidence has implicated the cholinergic system in the pathophysiology of schizophrenia (Raedler et al., 2007) . However, surprisingly little is known about the underlying neurobiological mechanisms of the association between anticholinergic activity and cognitive impairment in schizophrenia. Investigation of the neurobiologic correlates of anticholinergic-associated neurocognitive deficits could have vital implications for the development of novel medications that do not burden the cholinergic subsystems of the brain and may further the understanding of the neuropathophysiology of schizophrenia.
There have been several investigations of the iatrogenic effects of anticholinergic activity, a broad term incorporating nonspecific muscarinic receptor antagonistic action, on neurocognitive functioning in schizophrenia. For instance, Minzenberg et al. (2004) measured anticholinergic activity with a pharmacological index formulated from a collection of in vitro studies of muscarinic receptor antagonism and a clinical index of anticholinergic side effects rated by clinicians. With these two measures of anticholinergicity, they found that impairments in memory, recall, and complex attention were related to higher anticholinergic activity. Tracy et al. (2001) 
